Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14343798 | 1.00 | OPRD1 (0.54) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4577080 | 1.00 | OPRD1 (0.54) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4577161 | 0.93 | CYP1A2 (0.57) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4576658 | 0.93 | OPRD1 (0.53) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL14343543 | 0.93 | OPRD1 (0.53) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL7617589 | 0.92 | OPRD1 (0.54) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4585705 | 0.92 | OPRD1 (0.56) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4576801 | 0.90 | CYP3A4 (0.58) | OPRD1CYP1A2CYP3A4OPRM1OPRK1 | |
| SCHEMBL8930420 | 0.89 | CYP1A2 (0.61) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4576799 | 0.89 | CYP1A2 (0.54) | OPRD1CYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2016-07-14 | — | — | US | disclosed |
| US-9296707-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-8865721-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575169-B2 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8551998-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | CHANG KWEN-JEN (US) | 2013-02-28 | — | — | US | disclosed |
| EP-1469850-B1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC | 2012-08-30 | — | — | US | disclosed |
| EP-1469850-A4 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070173515-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | MOUNT COOK BIOSCIENCES, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1469850-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003057223-A9 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-10-02 | — | — | US | disclosed |
| WO-2003057223-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 760/4885CYP3A4 675/4885 |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885CYP1A2 656/4885CYP3A4 804/4885 |
| US-20070173515-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 760/4885CYP3A4 675/4885 |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 760/4885CYP3A4 675/4885 |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 760/4885CYP3A4 675/4885 |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885CYP1A2 656/4885CYP3A4 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.